Human · observational — Human observational evidence only — no trials.
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered from 1 recent study; not yet curated.
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
4 published studies by what they were done in. Lab and animal findings often do not carry over to people.
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Tracking 4 published studies of Mirvetuximab Soravtansine: 2 in humans, 2 reviews/other.
Reported direction across studies: 2 positive, 1 mixed, 1 negative.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Mirvetuximab Soravtansine works.
Cancers named in these studies
International journal of molecular sciences · May 2025 · review
This review summarizes the role of folate receptor alpha (FRα) in ovarian cancer, noting that FRα is frequently overexpressed in high-grade serous ovarian carcinoma. It describes that a VENTANA IHC assay is approved as a companion diagnostic to select patients (≥75% tumor cells with moderate to strong membrane staining) for the FRα-targeted antibody-drug conjugate mirvetuximab soravtansine, and discusses biological significance, IHC technical issues, and heterogeneity of expression across subtypes and tissue samples.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Gynecologic oncology · Jan 2025 · retrospective study
This retrospective study looked at 425 tumor samples from people with ovarian, fallopian tube, or primary peritoneal cancers to see how often folate receptor alpha (FRα) was present. FRα was found in 36.3% of cases and was more common in high-grade serous ovarian tumors and in samples from the ovary, fallopian tube, adnexa, or dominant pelvic masses than in metastatic sites. The study also found that some patients had different FRα results in different specimens, suggesting variability in testing results across samples.
Reported effect: positive rates 44.4%, p=0.02
Useful for understanding FRα testing patterns relevant to selecting patients for FRα-targeted therapy, but it does not evaluate anticancer efficacy.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Cornea · Feb 2019 · case series
This case series describes five women receiving mirvetuximab soravtansine who developed bilateral corneal subepithelial opacities and symptoms such as blurred vision and tearing. Imaging (AS-IR and AS-OCT) showed hyporeflective, likely cystic, subepithelial lesions. With a short course of topical steroids and lubricants, all patients' corneas cleared and visual acuity fully recovered.
Reported effects: average age 62.4, n=5 · blurred vision (n) 5, n=5 · +5 more
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
Annals of oncology : official journal of the European Society for Medical Oncology · Nov 2017
This short review summarizes recent therapeutic directions in ovarian cancer. It states that PARP inhibitors have been demonstrated as the most effective drug since platinum in high-grade serous or endometrioid ovarian cancer and highlights immunotherapy, VEGF inhibitors, PARPi combinations, cell-cycle modulators, p53-targeting strategies, lurbinectedin, and mirvetuximab soravtansine as areas of active development.
Studied with: chemotherapy, vascular endothelial growth factor inhibitor, PARPi, cell cycle modulators.
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed
The latest additions to Mirvetuximab Soravtansine's evidence base, and anything that's been retracted.
Recently addedWhere at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Human observational evidence only — no trials.
Largest credible effect: average age 62.4, n=5 PMID 30379722 · effect sizes 2–62.4 across 7 studies
Most authoritative study: Ocular Toxicity of Mirvetuximab
Human observational evidence only — no trials.
Largest credible effect: positive rates 44.4%, p=0.02 PMID 39631181
Most authoritative study: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Human observational evidence only — no trials.
Largest credible effect: average age 62.4, n=5 PMID 30379722 · effect sizes 2–62.4 across 7 studies
Most authoritative study: Ocular Toxicity of Mirvetuximab
Human observational evidence only — no trials.
Largest credible effect: positive rates 44.4%, p=0.02 PMID 39631181
Most authoritative study: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Human observational evidence only — no trials.
Largest credible effect: average age 62.4, n=5 PMID 30379722 · effect sizes 2–62.4 across 7 studies
Most authoritative study: Ocular Toxicity of Mirvetuximab
Human observational evidence only — no trials.
Largest credible effect: positive rates 44.4%, p=0.02 PMID 39631181
Most authoritative study: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
No primary experimental studies yet.
Most authoritative study: New treatments in ovarian cancer
No primary experimental studies yet.
Most authoritative study: New treatments in ovarian cancer
No primary experimental studies yet.
Most authoritative study: Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
No primary experimental studies yet.
Most authoritative study: Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
No primary experimental studies yet.
Most authoritative study: Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
1 ongoing · 3 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.